2 Minute Medicine
2 Minute Medicine® was established in 2012 by Dr. Marc D. Succi, a physician affiliated with Harvard Medical School and Massachusetts General Hospital. The aim was to address the need for reliable curation and precise reporting within the medical literature landscape. Each report from 2 Minute Medicine is authored and peer-reviewed by a medical professional. Initially, the focus was on creating brief, curated summaries of studies to help doctors stay informed about new medical findings. However, the organization quickly expanded its reach globally, recognizing a widespread demand for objective, high-quality, and concise medical reporting beyond just Harvard. At the core of our content is a unique tiered reporting system. Summaries are neatly organized in a format we call the “2 Minute Rundown,” similar to what one might share with colleagues in a hospital setting. We prioritize high-quality evidence, selecting information from systematic reviews, meta-analyses, randomized trials, and a select few high-quality observational studies. For those wanting more detail, our In-Depth sections provide comprehensive insights.
Outlet metrics
Global
#992757
United States
#427723
Health/Medicine
#2930
Articles
-
1 month ago |
2minutemedicine.com | Neel Mistry
1. Ischemic stroke occurred less often in patients with atrial fibrillation on DOACs compared to those on placebo. 2. Patients in the DOAC group reported an increased risk of intracerebral hemorrhage. Evidence Rating Level: 1 (Excellent)Study Rundown: Patients with atrial fibrillation are often prescribed direct oral anticoagulants (DOACs) to reduce the risks of thromboembolism and stroke.
-
1 month ago |
2minutemedicine.com | Neel Mistry
1. Perinatal mortality and neonatal morbidity were comparable between the atosiban and placebo groups. 2. Maternal adverse events were similar among patients who received atosiban versus placebo. Evidence Rating Level: 1 (Excellent)Study Rundown: Tocolytic medications are commonly used to delay preterm birth. Atosiban, an oxytocin receptor antagonist, is one such tocolytic used for threatened preterm labor. However, the effect of atosiban on improving neonatal outcomes remains unclear.
-
1 month ago |
2minutemedicine.com | Neel Mistry
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade 3 or greater treatment-related adverse events were more common in ivonescimab. Evidence Rating Level: 1 (Excellent) Study Rundown: Ivonescimab is a bispecific antibody targeting programmed cell death ligand-1 (PD-L1) and vascular endothelial growth factor (VEGF), showing promising results in early trials for advanced non-small cell lung cancer (NSCLC).
-
1 month ago |
2minutemedicine.com | Neel Mistry
1. There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and well-tolerated compared to placebo. Evidence Rating Level: 1 (Excellent)Study Rundown: GLP-1 receptor agonists have shown neuroprotective effects in laboratory models of Parkinson’s disease. However, it remains unclear whether these medications can modify the course of the disease in clinical practice.
-
1 month ago |
2minutemedicine.com | Neel Mistry
1. There were no gastric and adrenal puncture instances among patients who underwent radio-ablation in both groups. 2. Majority of patients achieved either complete or partial biochemical cure post-ablation. Evidence Rating Level: 2 (Good)Study Rundown: Diagnostic and therapeutic measures for the management of aldosterone-producing adrenal adenomas (APAs) are often invasive.
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Contact Forms
Contact Form
Website
http://2minutemedicine.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →